Elan to Start Paying Dividends

Elan (UNKNOWN: ELN.DL2  ) announced that it is to launch a "unique" dividend policy. The company is to pay a disbursement to its shareholders directly from the monies generated by Tysabri, a multiple sclerosis drug it developed and ultimately sold to its partner Biogen.

Elan said the dividend will be a certain percentage of the royalties Biogen pays for Tysabri, and that it expects to make two distributions per year. The first disbursement is to be 20% of the royalty total.

Last year, in-market sales of Tysabri amounted to $1.6 billion.

Elan's announcement comes on the heels of a buyout bid from financial investor Royalty Pharma, which has offered $6.55 billion ($11 per share) for the company.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2292385, ~/Articles/ArticleHandler.aspx, 10/22/2014 8:28:41 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement